The Patent Finder
UP

Ucb Pharma S.A.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

51 patents currently held

95 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
35 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Of the 95 now held by other companies, 35 name Ucb Biopharma SPRL as their current owner, and 60 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Dec 2026
Next term end
30
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Polyvinylpyrrolidone for the Stabilization of a Solid Dispersion of the Non-Crystalline Form of Rotigotine US 9,925,150
Cited by 13 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Ends Mar 2032 · High confidence
Also notable
Bacterial Host Strain US 9,109,216
Cited by 22 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Ends Jun 2031 · High confidence
Also notable
Protein Purification US 9,309,280
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2032.
Ends Sep 2032 · High confidence

Formerly held, still cited

Notable
Cited by 62 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Ucb Biopharma SRL
Ends Feb 2029 · High confidence
Also notable
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2032.
Ends Jun 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 16 to 25, 2027 · next Jan 16
  • 1 fee due Feb 18, 2027
    The maintenance fee for Bacterial Host Strain (US 9,109,216) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
  • 1 fee due May 21, 2027
    The maintenance fee for Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides (US 11,820,746) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
  • 1 fee due Jun 26, 2027
    The maintenance fee for Anti-Sclerostin Antibodies and Their Use to Treat Bone Disorders as Part of a Regimen (US 11,851,483) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 1 fee due Aug 13, 2027
    The maintenance fee for Treatment for Bone Diseases (US 11,896,667) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
  • 1 fee due Sep 26, 2027
    The maintenance fee for Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides (US 11,939,319) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
  • 2 fees due Oct 12 to 19, 2027 · next Oct 12
  • 1 fee due Nov 7, 2027
    The maintenance fee for Substituted Alkoxypyridinyl Indolsulfonamides (US 11,976,056) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 4 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,670,621Transdermal Administration of (R)-3,3-Diphenylpropylamin-MONOESTERS
In force
 · High confidence
In forceHigh confidence
US 8,604,051Thieno-Pyridine Derivatives as Mek Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 9,309,215Chiral Intermediate, Process for Producing the Same and Its Use in the Manufacture of Tolterodine, Fesoterodine, or the Active Metabolite Thereof
In force
 · Low confidence
In forceLow confidence
US 7,807,715Pharmaceutical Compositions Comprising Fesoterodine
In force
 · High confidence
In forceHigh confidence
US 9,364,541Pharmaceutical Compositions Comprising Fesoterodine
In force
 · Medium confidence
In forceMedium confidence
US 9,095,557Anticonvulsant Combination Therapy
In force
 · Medium confidence
In forceMedium confidence
US 9,446,011Anticonvulsant Combination Therapy
In force
 · High confidence
In forceHigh confidence
US 7,982,058Chiral Intermediate, Process for Producing the Same and Its Use in the Manufacture of Tolterodine, Fesoterodine, or the Active Metabolite Thereof
In force
 · High confidence
In forceHigh confidence
US 8,969,036Process for Obtaining Antibodies
In force
 · High confidence
In forceHigh confidence
US 8,246,979Transdermal Delivery System for the Administration of Rotigotine
In force
 · High confidence
In forceHigh confidence
10 of 51 patents shown.
Pro members see all 51.
Pro members: see all 51 patents
Also on record, not counted in the 51: 95 patents in force now held by others · 243 patents ended · 19 applications pending · 130 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited